title: Evaluation of the association of proximal coronary culprit artery lesion location with clinical outcomes in acute myocardial infarction.
abstract: Impaired coronary artery blood flow and left anterior descending (LAD) artery culprit location are angiographic variables that have been associated with poorer outcomes after fibrinolytic administration in patients with acute myocardial infarction (AMI). We hypothesized that culprit lesion location in the proximal portion of the culprit artery would also be associated with poorer clinical outcomes compared with a mid or distal location. Lesion location and clinical outcomes were evaluated in 2,488 patients from the Thrombolysis In Myocardial Infarction (TIMI) 4, 10A, 10B, and 14 trials. Proximal lesions were located before or at the first major branch of the parent artery, mid lesions were between the first and the second major branches, and all other lesions were classified as distal. Proximal lesions were associated with a higher incidence of in-hospital death or recurrent AMI compared with mid or distal lesions (10.5% [n = 478] vs 6.1% [n = 1,498] vs 3.7% [n = 511], p <0.001), and they were associated with a higher rate of in-hospital death (6.7% [n = 478] vs 3.2% [n = 1,498] vs 2.5% [n = 511], p = 0.001). In a multiple logistic regression model adjusting for TIMI flow grade, age, gender, and pulse, the planimetered distance from the ostium to the LAD culprit lesion was associated with 30-day death or recurrent AMI (odds ratio 0.79 per centimeter increase in distance down the artery, p = 0.01). Proximal culprit lesion location is associated with an increased risk of adverse outcomes after fibrinolytic administration, which is likely due to a larger area of subtended myocardium. In patients with a LAD culprit lesion, proximal lesion location is a multivariate correlate of adverse outcomes even after adjustment for coronary blood flow and other covariates.
authors.affiliation: TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham & Women's Hospital, Boston, Massachusetts, USA.
authors.forename: Juhana
authors.initials: J
authors.lastname: Karha
authors.forename: Sabina A
authors.initials: SA
authors.lastname: Murphy
authors.forename: Ajay J
authors.initials: AJ
authors.lastname: Kirtane
authors.forename: James A
authors.initials: JA
authors.lastname: de Lemos
authors.forename: Julian M
authors.initials: JM
authors.lastname: Aroesty
authors.forename: Christopher P
authors.initials: CP
authors.lastname: Cannon
authors.forename: Elliott M
authors.initials: EM
authors.lastname: Antman
authors.forename: Eugene
authors.initials: E
authors.lastname: Braunwald
authors.forename: C Michael
authors.initials: CM
authors.lastname: Gibson
mesh_terms: D000208:Acute Disease; D017023:Coronary Angiography; D003331:Coronary Vessels / Q000473:pathology*; D004562:Electrocardiography; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D017052:Hospital Mortality; D006801:Humans; D015994:Incidence; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D011237:Predictive Value of Tests; D012008:Recurrence; D016019:Survival Analysis; D014481:United States
chemical_list: D005343:Fibrinolytic Agents